Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Azithromycin had a potent in vitro activities and broad spectrum from typical and atypical
 bacteria to anaerobes. Azithromycin intravenous formulation demonstrated high efficacy and
 eradication rate in the western clinical trials. Development of azithromycin intravenous
 formulation would bring the clinical benefit to patients with pelvic inflammatory disease
 (PID) in Japan.
Inclusion Criteria:

 Both of following symptoms should be observed.

 -  Lower abdominal pain and/or lower abdominal tenderness.

 -  Hypochondrial pain and/or hypochondrial tenderness (tenderness of uterus or adnexa of
 uterus).

 Exclusion Criteria:

 Known or suspected hypersensitivity or intolerance to azithromycin, other macrolides, or
 ketolides.

 Hepatic dysfunction (AST, ALT, total bilirubin > 3 times institutional normal).